MILREM-ROBOTICS
25.11.2021 09:02:10 CET | Business Wire | Press release
The iMUGS Consortium, in charge of a 32,6 MEUR project developing the European standard unmanned ground system (UGS), demonstrated how defence forces can use tactical 4G/5G communications networks and UGS’ equipped with ISR and signal intelligence payloads, jammers, acoustic sensors, and various other technology to conduct missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125005387/en/
The demonstration that was performed in September in Latvia, was led by LMT, a member of the integrated Modular Unmanned Ground System (iMUGS) consortium, with the support of the project coordinator Milrem Robotics and featured an ensemble of different technology.
Latvian National Armed Forces used two Milrem Robotics’ THeMIS Unmanned Ground Vehicles (UGV) during two scenarios to display the benefits of teaming up manned units with unmanned systems.
One THeMIS UGV was equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT) provided by The Electronic Communications Office of Latvia, Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios (Tough SDR Vehicular), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The RWS integration was part of the demonstration, but not of the iMUGS project itself.
The second THeMIS, used as a mule for transporting the squad’s equipment, was equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular.
The units and UGVs used Bittium’s tactical communication network TAC WIN combined with LMT’s commercial 4G and a tactical 5G-SA bubble provided by Bittium and Cumucore.
In addition, Krauss-Maffei Wegmann’s (KMW) Dingo infantry mobility vehicle was used as the command centre from where UGVs were operated in Line of Sight (LOS) and Beyond the Line of Sight (BLOS) mode using Bittium’s SDR radios and to where the ISR and Signal Intelligence sensor feed was relayed and incorporated into LMT’s Battle Management System Viedsargs.
“The displayed scenarios showed that unmanned systems, enhanced with innovative communication systems and various defence technology, can be used for collecting and sharing tactical information, improve situational awareness, decrease troops physical load, and increase force protection,” explained Kuldar Väärsi, CEO of Milrem Robotics.
''For the first time ever, in a special network, a tactical network was connected with a stand-alone 5G network. This allowed communication between units and robots, as well as collecting information from sensors and placing this information into LMT’s Battle Management System "Viedsargs'','' said Ingmars Pukis, Vice President and Member of the Management Board of LMT.
Additional equipment used in the demonstration included: SRC Brasa's NATRIX UGV used for CASEVAC, high-speed First-Person View drone, Vertical Take-off, and Landing UAV STAR, and a gunshot detection and source recognition audio sensor by Riga Technical University (RTU).
The iMUGS project was launched in 2020 to develop a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems. Its goal is to standardize a Europe-wide ecosystem for ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.
The system will use an existing UGV – Milrem Robotics’ THeMIS – and a specific list of payloads.
The project’s progress is displayed during six demonstrations. „So far Milrem Robotics and LMT Innovations have set the bar very high. Which means we have some great things to wait for as the main results of the iMUGS projects are yet to be seen,“ said Martin Jõesaar from the Estonian Center for Defence Investments, the representative of the participating Member States in the iMUGS Project. The next demonstration will take place in Q1 of 2022 in Finland.
iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Bittium, Diehl Defence, dotOcean, GMV Aerospace and Defence, Insta Advance, Krauss-Maffei Wegmann, Latvijas Mobilais Telefons (LMT), NEXTER Systems, Royal Military Academy of Belgium, Safran Electronics & Defense, Sol.One and Talgen Cybersecurity.
Watch the Demo 2 Scenarios here:
https://www.youtube.com/watch?v=-_iLCV3Ob2I
https://www.youtube.com/watch?v=HbK_ixrTuWU
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005387/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
